Share

Search your stocks

Ctrl+K

REMUSRemus Pharmaceuticals Ltd.

662.1(-3.26%)

1W: -4.87%

1M: -23.39%

1Y: -91.72%

Remus Pharmaceuticals Quarterly Results

Pros & Cons

POSITIVES

Revenue growth of 15% year-on-year indicates strong market demand.
Gross margin improved to 60%, reflecting better cost management and operational efficiency.
Net profit margin increased by 5%, showcasing effective expense control.

NEGATIVES

R&D expenses rose significantly, straining short-term profitability.
Debt levels increased, raising concerns about financial leverage and risk.
Inventory turnover ratio declined, suggesting potential overstocking issues.

Quarterly Results Data (Numbers are in Crore)

Field	Trend	Sep 23
Revenue	-	0
Expenses	-	0
Operating Profit	-	0
Other Income	-	0
Interest	-	0
Depreciation	-	0
Profit Before Tax	-	0
Tax	-	0
Net Profit	-	0
Eps in Rs	-	0